OPERA: Observational Study of Perception of Information and Quality of Life in Patients with Neuroendocrine Tumors Starting Lanreotide – Study Design Abstract #2100

Introduction: Information provided to patients about burden and treatment of neuroendocrine tumors (NETs) may ease treatment adherence, outpatient monitoring, and improve quality of life (QoL), but can also cause anxiety. Data on how to individually adapt materials are insufficient and mainly derived from clinical trials.
Aim(s): To describe the evolution of patients’ perception of information and QoL within 6 months of treatment initiation in routine clinical care.
Materials and methods: In this non-interventional, prospective, multicentre cohort study, 50 specialist physicians at French reference centres for NET care will consecutively enrol 115 patients with histologically confirmed G1 or G2 gastroentero- (GEP-)NETs for whom the decision to initiate treatmentment with lanreotide autogel 120mg /28 days has already been taken. Patients will complete self-administered questionnaires before treatment initiation, and at 3 (M3) and 6 (M6) months. Perception of information (QLQ-INFO25), QoL (QLQ-C30) and clinical parameters will be assessed at these 3 time points; coping (Brief COPE) will be assessed at baseline.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Vincent Hautefeuille

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1885 Web-Based Tailored Information and Support for Patients with a Neuroendocrine Tumor
Introduction: Patients with a neuroendocrine tumour (NET) frequently experience physical and psychosocial complaints. Novel strategies to provide information to optimize supportive care in these patients are of interest.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Others
Presenting Author: drs Ld de Hosson
#636 Illness Perceptions, Risk Perception and Worry in Patients with Inherited Paragangliomas
Introduction: Carriers of germline mutations in subunits B and D of the succinate dehydrogenase (SDH) gene are at risk for developing paragangliomas (PGLs). The way a person perceives this risk and worries about it may be influenced by his or her perceptions about PGLs.
Conference: 10th Annual ENETS Conference (2013)
Category: Pathology, grading, staging
Presenting Author: MD Leonie Van Hulsteijn
#881 Web-Based Tailored Information and Support for Patients with a Neuroendocrine Tumor
Introduction: Patients with neuroendocrine tumors (NET) frequently experience physical and psychosocial complaints. Optimal patient information can form an essential aspect of supportive care. To give NET patients continuous access to information, we developed a web-based tailored information and support system.
Conference: 11th Annual ENETS Conference (2014)
Category: ...none of the below
Presenting Author: MD Grietje Bouma
#2263 Patient Survey Devoted to Characterizing Experience and Expectations of Patients with Neuroendocrine Tumors (NET)
Introduction: Patients (pts) with NET experience consequences of disease progression and treatments; their preferences can influence the choice and success of therapeutic strategies.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Dr Matthieu Sarabi
Authors: Sarabi M, Gueguen D, Walter T, Hentic O, ...
#1178 Treatment Satisfaction, Symptom Control and Quality of Life (QoL) with Lanreotide Autogel (LAN) in NET Patients with Carcinoid Syndrome (CS): Results from the SYMNET Study
Introduction: CS associated with NETs can have a negative impact on patients’ QoL.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Philippe Ruszniewski
Keywords: quality of life